Federated Investors Inc. PA acquired a new stake in Inspire Medical Systems (NASDAQ:INSP) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 307,034 shares of the company’s stock, valued at approximately $10,949,000.

Several other hedge funds have also made changes to their positions in the company. Rhumbline Advisers acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at $243,000. Dean Capital Investments Management LLC acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at $857,000. Wasatch Advisors Inc. acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at $1,065,000. Sei Investments Co. acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at $1,093,000. Finally, EAM Global Investors LLC acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at $1,130,000.

INSP opened at $56.99 on Wednesday. Inspire Medical Systems has a twelve month low of $22.50 and a twelve month high of $57.02.

Inspire Medical Systems (NASDAQ:INSP) last posted its earnings results on Tuesday, August 7th. The company reported ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.08. The firm had revenue of $10.94 million during the quarter, compared to the consensus estimate of $9.30 million.

A number of brokerages have recently issued reports on INSP. Zacks Investment Research cut shares of Inspire Medical Systems from a “buy” rating to a “hold” rating in a research note on Thursday, August 9th. Stifel Nicolaus started coverage on shares of Inspire Medical Systems in a report on Tuesday, May 29th. They issued a “buy” rating and a $42.00 target price on the stock. Guggenheim started coverage on shares of Inspire Medical Systems in a report on Tuesday, May 29th. They issued a “buy” rating and a $40.00 target price on the stock. Goldman Sachs Group started coverage on shares of Inspire Medical Systems in a report on Tuesday, May 29th. They issued a “neutral” rating and a $25.00 target price on the stock. Finally, Bank of America started coverage on shares of Inspire Medical Systems in a report on Tuesday, May 29th. They issued a “neutral” rating and a $36.00 target price on the stock. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $38.17.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Featured Story: NASDAQ

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems (NASDAQ:INSP).

Institutional Ownership by Quarter for Inspire Medical Systems (NASDAQ:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.